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INTRODUCTION
Cervical cancer is the second most prevalent cancer
among women worldwide and the main cause of
death, especially in young women. Approximately
500,000 new cases registered each year out of
which 250,000 cases are attributable deaths ac-
cording to the World Health Organization (WHO)
statistics.1 Approximately 90% of the cervical
cancer deaths are in developing countries
compared to other regions.2
Human papilloma virus is a DNA virus that
infected skin and mucous in the lower genital
tract. Approximately 95% incidence of cervical
carcinoma associated with oncogenic HPV types;
HPV 16 and 18 are the most prominent oncogenic
HPV types found for more than 62% in cervical
carcinoma. In addition to HPV infection, the inci-
dence of cervical carcinoma increase with sexual
activity, parity, pregnancy, smoking and oral con-
traceptive use.1
Abstract
Objective: To evaluate the correlation between HPV-16 and 18
infection and the cervical cytology changes among combination
hormonal contraceptives users.
Methods: A cross-sectional study involved 40 women using
combined hormonal contraceptive (oral or injection/DMPA contra-
ceptive) and 40 women of non-hormonal contraceptive users was
conducted in Dr. Wahidin Sudirohusodo hospital, some affiliated
hospitals of Department of Obstetrics and Gynecology Faculty of
Medicine, Universitas Hasanuddin and a private clinic in Makassar
from November 2015 and April 2016. HPV 16 and 18 genotyping
in cervix using PCR method and cervical cytology changes using
liquid-based cytology (LBC) method were performed. HPV infection
and cervical cytology changes were analysis based on Fisher’s test
and chi-square test.
Results: A significant difference found only in parity (p<0.05)
between users and control of baseline characteristics. Neither users
nor control were significantly associated with HPV-16 and 18
infection and changes in cervical cytology.
Conclusion: Combined hormonal contraceptives are not correlated
with HPV-16 and 18 infection and changes in cervical cytology.
[Indones J Obstet Gynecol 2018; 6-3: 188-192]
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Abstrak
Tujuan: Untuk mengetahui hubungan antara HPV-16 dan 18 infeksi
dan perubahan sitologi serviks pada akseptor kontrasepsi hormonalkombinasi.
Metode: Penelitian potong lintang pada 40 perempuan akseptorkontrasepsi hormonal kombinasi (oral atau injeksi/DMPA kontra-
sepsi) dan 40 perempuan bukan akseptor kontrasepsi hormonal kom-
binasi dilakukan di rumah sakit Dr. Wahidin Sudirohusodo, beberaparumah sakit afiliasi dari Departemen Obstetri dan Ginekologi Fakultas
Kedokteran Universitas Hasanuddin dan klinik swasta di Makassardari November 2015 dan April 2016. Pemeriksaan genotip HPV 16 dan
18 dari serviks dilakukan dengan metode PCR dan pemeriksaan
sitologi serviks menggunakan metode sitologi berbasis cairan (liquidbased cytology). Infeksi HPV dan perubahan sitologi serviks analisis
dengan uji Fischer dan uji chi-square.
Hasil: Perbedaan bermakna antara akseptor kontrasepsi hormonal
kombinasi dan kontrol hanya terdapat pada paritas (p<0,05) padakarakteristik sampel penelitian. Baik akseptor kontrasepsi hormonal
kombinasi maupun kontrol tidak berkorelasi bermakna dengan infeksi
HPV-16 dan 18 dan perubahan sitologi pada serviks.
Kesimpulan: Kontrasepsi hormonal kombinasi tidak berkorelasi de-
ngan infeksi HPV-16 dan 18 dan perubahan sitologi pada serviks.
[Maj Obstet Ginekol Indones 2018; 6-3: 188-192]
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Previous studies have shown that hormonal
contraceptives use associated with HPV infection.
Oral hormonal contraceptives use for more than
six years associated with the prevalence of HPV
infection in women aged 20-37 years in Thailand
after controlling for sexual activity and cervical
cytologic abnormalities. Current use of oral
contraceptive also associated with HPV 16 and 18
seropositive.3 A study has also found that current
users of oral contraceptive had a lower risk of HPV
infection compared to current users of inject-
ables users.4 Therefore, hormonal contraceptive
use increased persistent HPV infection.5
Estrogen and progestin in combined hormonal
contraceptive affect the cervical cytology. Oral
contraceptive cause cervical hypertrophy, hyper-
secretion and proliferation of endocervical gland
that results in increased cervical mucus secre-
tion, mucous edematous and pseudodecidualiza-
tion. These are due to gestagen that contained in
birth control pills. In addition, gestagen also causes
metaplasia and epithelial dysplasia in the epithelial
of portio and endocervical mucous membranes.6
Hormonal contraceptives maintained the columnar
epithelial cells in the ectocervix and transformation
zone (cervical ectopy). Cervical ectopy occurs
when columnar epithelium found in the endo-
cervical area extends out on to the ectocervix.
Cervical ectopy is common in young women,
pregnant women and hormonal contraceptive
users. Some hypothesise that hormonal contra-
ceptive users biologically more vulnerable to HPV
infection than non-users.5,7 Our study aimed to
evaluate the correlation between HPV-16 and 18
infection and the cervical cytology changes among
combination hormonal contraceptives users.
METHODS
This cross-sectional study involved combined
hormonal contraceptive users (oral and injection/
DMPA contraceptive) in Dr. Wahidin Sudirohusodo
hospital, some affiliated hospitals of Department of
Obstetrics and Gynecology Faculty of Medicine,
Universitas Hasanuddin and a private clinic in
Makassar from November 2015 and April 2016.
As controls, we enrolled women of non-hormonal
contraceptive users. The inclusion criteria
consisted of using combined hormonal contra-
ceptives for at least 2 years, age of first sexual
intercourse 20 years, history of normal delivery
for four times maximum, one sexual partner, no
smoking, alcohol and drugs, and not being treated
with antibiotics. Exclusion criteria were non-users
of combined hormonal contraceptives suffering
from cervical carcinoma, having sexual intercourse
within 3 days prior to the examination and
menstruation. This study was approved by the
Health Research Ethics Committee of Faculty of
Medicine, Universitas Hasanuddin. All participants
provided written informed consent prior to the
start of the study. HPV 16 and 18 genotyping in
cervix using PCR method and cervical cytology
changes using liquid-based cytology (LBC)
method.
A total 101 women were enrolled in this study.
There were three women at enrollment who were
excluded, and 18 women were drop out from this
study. Therefore, 80 women (n=80) were eligible
for analysis in this study. The statistical analysis
was based on Fisher’s test and chi-square test. A
p-value less than 0.05 was considered statistically
significant.
RESULTS
The study included 40 women using combined
hormonal contraceptives, and 40 women do not
use this contraceptives method as control. Women
in users group were aged between 20 and 35 years
(72.5%), high education (82.5%), age of first sexual
intercourse between 20 and 29 years (100%),
multiparity (70%) and more than 3 years of using
this contraceptive method (67.5%) compared to
control (65%; 97.5%; 90%; 47.5%; 42.5%;
respectively). The only significant difference found
in parity between users and control (p<0.05).
Baseline characteristics of the women in this study
are summarized in Table 1.
HPV 16 infection detected only in one user
(2.55) than none in control otherwise in HPV 18
infection. There was no significant correlation
(p>0.05) between HPV-16 and 18 infection and
combined hormonal contraceptives (Table 2).
Cervical cytology using LBC method show cervical
changes in 24 (60%) of combined hormonal con-
traceptives users compared to 19 (47.5%) in con-
trol. There were no significant cervical cytology
changes between users and control group (Table
3).
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Table 3. Cervical Cytology Results using Liquid-based Cy-
tology (LBC) Method
Changes in cervical cytology
Subjects Positive Negative p
n % n %
Users (n=40) 24 60 16 40 0.26
Control (n=40) 19 47.5 21 52.5
DISCUSSION
In the present study, we found that there was no
significant difference of HPV types 16 and 18
infections between combined hormonal contra-
ceptive users and control. This result similar to the
study by Morgan et al. that follow up 1135 women
(consists of 376 combined oral contraceptives
users, 331 DMPA users and 428 non-contraceptive
users) for 18 months. They found new HPV infec-
tion in 269 women and high-risk HPV infection in
157 women.8 However, HPV infection and COCs
was not statistically significant after adjusting
for age, a number of sexual partners, bacterial
Table 1. Baseline Characteristics of Study Participants
Characteristics Users (n=40) Control (n =40)
p
n % n %
Age (years)
20 - 35 29 72.5 26 65 0.469
>35 11 27.5 14 35
Education
Low (<SMA) 7 17.5 1 2.5 0.057
High (>SMU) 33 82.5 39 97.5
Occupation
Working 20 50 28 70.0 0.068
Not working 20 50 12 30.0
Age of first sexual intercourse (years)
20 - 29 40 100 36 90 0.116
30 - 39 0 0 4 10
Parity
Nulli/Primipara 10 25 21 52.5 0.012
Multipara 30 75 19 47.5
Duration of contraceptive use (years)
 3 13 32.5 23 57.5 0.235
> 3 27 67.5 17 42.5
Table 2. HPV 16 and 18 Infections in the Cervix of Study Participants
HPV 16 HPV 18
Subjects Positive Negative p Positive Negative p
n % n % n % n %
Users (n=40) 1 2.5 39 97.5 1.000 0 0 40 100 1.000
Control (n=40) 0 0 40 100 1 2.5 39 97.5
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vaginosis and duration of the COCs and DMPA use.
Study also that COCs was not associated with the
risk of cervical infection whereas DMPA use signifi-
cantly associated with the risk of cervical infection
primarily by chlamydial and gonococcal infections5
but in another study show that cervical carcinoma
risk increases by up to four-fold in women positive
for cervical HPV DNA after long-term use of oral
contraceptives.9 Study by Urban show that use of
oral and of injectable hormonal contraceptives was
associated with a transiently increased risk of
breast and cervical cancer after using the contra-
ceptives for 5 years but not differ significant.10
Although women are infected with HPV cervical,
most do not develop into cervical cancer. Several
factors are also involved in the development of
cervical cancer. Exogenous or environmental
factors such as the use of hormonal contraceptives,
smoking, parity and infections along with sexually
transmitted diseases; viral factors such as the
specific type of infection, co-infection with other
HPV types, variants of HPV, viral load and viral
integration; and host factors include endogenous
hormones, genetic factors and other factors related
to the immune response.11 The number of full-term
pregnancies is associated with an increased risk of
invasive cervical carcinoma after adjustment for
the number of sexual partners and age at first
intercourse.12 The mechanisms which high parity
increases the risk of cervical carcinoma is through
the maintenance of the transformation zone on the
ectocervix for many years in which may facilitate
exposure to HPV. A previous study found that high
parity increases the risk of squamous-cell carci-
noma of the cervix among HPV-positive women.13
This study finding multiparity significantly found
difference between users and control.
HPV infects immature basal cells of the
squamous epithelium in areas of the immature
metaplastic squamous present at the squamo
columnar junction. Cervix is a wide area with
immature metaplastic squamous epithelium
that is highly susceptible to HPV infection. HPV
replication took place immature squamous cells
results in koilocytotic atypiaconsists of atypic core
and halo perinuclear cytoplasmic. Perinuclear halo
show typical expression of active phase HPV infec-
tion in cervical cytology.14 Therefore, other types
of HPV infection may be present in the women
cervix of the present study both combined hor-
monal contraceptive users and control.
Cervical cytology results show cervical changes
both in users and control but the difference
not statistically significant. This results similar to
previous studies that found cervical histologically
change due to combined hormonal contraceptives
use. Effects of 17 -estradiol from COCs causes
progressive metaplasia in the transformation zone
that leads to dysplasia in squamous epithelium.15
These findings are in disagreement with results
from the study by Syrjanen et al., found that COCs
was not a significant predictor in women with
cervical intraepithelial neoplasia (CIN) b or high-
grade squamous intraepithelial lesion (HSIL) in
women with positive and negative HPV infection.
They also found that the disease with high-
oncogenic risk HPV types infection is not
correlated to contraception.16 Most HPV infection
is asymptomatic and does not change the cervical
tissue; therefore, cervical changes could not
be detected on Pap smear. Some studies found
the majority of HPV infections will regress
spontaneously within five years, but only a few
women with high-risk HPV infection will develop
into CIN b and will eventually cervical cancer.17,18
Estrogen increases expression of oncogenic
proteins E6 and E7 in HPV as a major stimulant of
cervical cancer.19 Steroid hormones (estrogen and
progesterone) play a role in the initiation and
progression of cervical cancer through carcino-
genesis. Lesions from HSIL develop into cervical
carcinoma reported from women using estra-
diol.15,20
CONCLUSION
In conclusion, our study show there is no relation-
ship between HPV 16/18 infection and cervical
cytology changes among combined hormonal
contraceptives users.
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